Senseonics Launches Freedom CGM Clinical Study
The company begins first-in-human testing of a glucose monitor that requires no external transmitter.
Updated on Oct. 26, 2026 in Diabetes
Live Poll
Would you prefer a medical monitoring device that requires no external wearable components?
Senseonics, headquartered in Germantown, has officially initiated a first-in-human clinical study for its new Freedom continuous glucose monitoring system. This device is engineered to function independently without the need for an external on-body transmitter.
Why it matters
The study aims to evaluate clinical safety and functionality while generating critical insights to inform a future pivotal study. Success in this trial could mark a significant shift toward more seamless glucose monitoring technology.
Preclinical testing of the system involved over 18,500 communication data points. The preferred antenna design achieved a 100 percent success rate during those evaluations.
The players
Senseonics
Senseonics is a medical technology company headquartered in Germantown that specializes in the development and manufacturing of long-term, implantable continuous glucose monitoring systems for people with diabetes.
The details
The Freedom system integrates both a battery and Bluetooth communication capabilities directly into the unit, utilizing the same core sensing technology as the Eversense 365 system. Researchers are currently using this human study to test the sensor's direct Bluetooth performance and device design safety.
Timeline
Q2 2026: Preclinical studies for the Freedom system were completed.
October 26, 2026: The first-in-human clinical study was initiated.
2027: A pivotal clinical study is expected to begin.
2028: A potential commercial launch for the system is targeted.
The Big Picture
This development represents an evolution of the sensing technology found in the Eversense 365 system. By eliminating the external transmitter, the device aims to bridge the gap between current medical monitoring capabilities and more discreet, integrated wearable solutions.
The study evaluates the functionality of a system designed to operate without an external on-body transmitter, which could eventually simplify daily glucose monitoring routines. Patients may eventually benefit from more discreet hardware, though clinical safety remains under evaluation.
The takeaway
Advancements in embedded communication technology are steadily removing the need for bulky external equipment in medical monitoring. Individuals tracking glucose levels should monitor upcoming pivotal trial results for insights into future device usability and availability.
What happens next
Senseonics expects to initiate a pivotal clinical study in 2027 and is targeting a potential commercial launch for the Freedom system in 2028.
Further reading
For more information on the current landscape of glucose monitoring technology, visit the Diabetes section.
Live Poll
Would you prefer a medical monitoring device that requires no external wearable components?
